Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
ESBATech
About
ESBATech develops fully human antibody fragments for therapeutic applications, applying the single-chain antibody framework.
- 51 - 100
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- Fr14.50M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 1998
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 14, 2002 | Series A | Fr14.50M | 1 |
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
